Key things to know about the first Covid 19 nasal spray- Fabispray

Today leading pharmaceutical company Glenmark has launched, its first nasal spray by the name “Fabispray” to treat covid -19. This is basically launched to treat adult patients with covid infection. After the completion of the clinical trial of the nasal spray, it was found that it helped to reduce the viral load by 94% in 24 hours and by 99% in 48 hours. These are some of the key points you should know about the first nasal spray for covid 19.

·         FabiSpray, will be useful in the treatment of adult patients with COVID-19 who have a high risk of progression of the disease.

·         It is designed to kill the virus in the upper airways

·         It possesses anti-microbial properties to check the spread of the virus.

·         It acts as a chemical and physical barrier to prevent it from reaching the lungs.

·        Glenmark received manufacturing and marketing approval from India's drug regulator, Drugs Controller General of India, for Nitric Oxide Nasal Spray as part of the accelerated approval process.